Skip to main content

Research Repository

See what's under the surface

Advanced Search

Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community (2019)
Journal Article
Chalmers, J., Wilkes, E., Harris, R., Kent, L., Kinra, S., Aithal, G., …Guha, I. N. (2020). Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Frontline Gastroenterology, 11(2), 86-92. https://doi.org/10.1136/flgastro-2019-101177

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. Objective: To describe the development of the Nottingham liver disease stratification pathway, present a 12-month evaluation of uptake and stratification results... Read More about Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community.

Biomarkers of liver fibrosis (2016)
Journal Article
Morling, J. R., & Guha, I. N. (in press). Biomarkers of liver fibrosis. Clinical Liver Disease, 7(6), doi:10.1002/cld.555

Currently the only accepted method (gold standard) for the diagnosis of the fibrotic stages of chronic liver disease (CLD) is liver biopsy, to allow histological assessment. Liver biopsy is an invasive investigation associated with a range adverse ev... Read More about Biomarkers of liver fibrosis.

γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study (2015)
Journal Article
Morling, J. R., Fallowfield, J. A., Williamson, R. M., Robertson, C. M., Glancy, S., Guha, I. N., …Price, J. F. (2015). γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia, 58(7), 1484-1493. https://doi.org/10.1007/s00125-015-3575-y

© 2015, The Author(s). Aims/hypothesis: We examined the association of prevalent and incident cardiovascular disease (CVD) with chronic liver disease in a cohort of community-based people with type 2 diabetes, in order to clarify the relationship bet... Read More about γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study.

Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study (2013)
Journal Article
Morling, J. R., Fallowfield, J. A., Guha, I. N., Nee, L. D., Glancy, S., Williamson, R. M., …Price, J. F. (2014). Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. Journal of Hepatology, 60(2), doi:10.1016/j.jhep.2013.10.017

BACKGROUND & AIMS: It is difficult to determine the different stages of non-alcoholic fatty liver disease without the use of invasive liver biopsy. In this study we investigated five non-invasive biomarkers used previously to detect hepatic fibrosis... Read More about Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study.


;